“Treating 5 percent of all hepatitis C patients with the latest drugs would be more effective at reducing infections and health care costs than the current approach, a new study shows.
The cost-benefits analysis by researchers from the USC Schaeffer Center for Health Policy and Economics and other institutions compares three treatment options to the current approach, or “baseline” scenario, which treats patients in the most advanced stages of the disease when they may need a costly liver transplant.
The researchers found that a “treat 5 percent” approach would reduce infections from 2.7 million to 39,000 cases in 50 years, compared with the current approach, relying on older drugs, which would reduce infections to 207,000 cases in 50 years. Under the “treat 5 percent” scenario, health care expenditures would drop below the baseline’s costs within 20 years of implementation.
The study, published Oct. 5 in the journal Health Affairs, is believed to be the first analysis to account for how the disease progresses in a patient and the ways in which it can spread.”
Source: MedicalExpress.com – October 7, 2015